ICCC - Immucell Corp
NYSE * Health Care * Biotechnology
$7.54
$-0.06 (-0.79%)
About Immucell Corp
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Key Statistics
Market Cap
$68.76M
P/B Ratio
2.58
EPS
$-0.12
Revenue Growth
-0.0%
Profit Margin
-0.0%
Employees
73
How ICCC Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
#6
of 6
Growth Rank
#5
of 6
Size Rank
#6
of 6
Immucell Corp Company Information
- Headquarters
- Maine; U.S.A
- Website
- immucell.com
- Sector
- Health Care
- Industry
- Biotechnology